817P - Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC)

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Renal Cell Cancer
Presenter Viktor Grünwald
Citation Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373
Authors V. Grünwald1, M. Dietrich2, G.R. Pond3
  • 1Clinic For Hematology, Hemostasis, Oncology And Stemcelltransplantation, Hannover Medical School, 30625 - Hannover/DE
  • 2Natural Sciences, Leibniz University Hannover, Hannover/DE
  • 3Oncology, Escarpment Cancer Research Institute, McMaster Medical Centre, Hamilton/CA

Abstract

Background

MSKCC and IMDC risk classification scores consist of clinical and laboratory parameters, which are able to classify patients prognosis. Baseline health related quality of life (HR-QoL) has been previously shown to have prognostic relevance in cancers. We therefore tested whether the addition of HR-QoL parameters to these tools can improve prognostic accuracy.

Methods

1100 1st line patients treated with sunitinib or pazopanib within the COMPARZ study (NCT00720941) were analyzed retrospectively. Baseline FACIT-Fatigue (F), FKSI-19 and the DRS-P subscale were used as continuous variable in prognostic factor analysis. Cox proportional hazards regression was performed to evaluate the potential prognostic ability of HR-QoL parameters on OS. Scores were adjusted for MSKCC and IMDC risk group scores separately.

Results

Univariable analysis on prognosis, adjusted for risk groups.

HR (CI95%) P
IMDC risk FACIT-F Favorable Intermediate Unfavorable Unknown Continuous 0.77 (0.37, 1.60) 1.42 (0.70, 2.87) 3.10 (1.50, 6.38) REFERENCE 0.97 (0.97, 0.98)

Conclusions

Our analyses indicate that baseline HR-QoL scores add to established risk prognosticators. However, only a single HR-QoL score should be used for further validation. Further study of discrimination ability is ongoing.

Clinical trial identification

NCT00720941

Legal entity responsible for the study

GSK sponsored clinical study, which is the data set for the current retrospective analysis

Funding

Medical School Hannover, Leibniz University, McMaster University

Disclosure

V. Grünwald: Honoraria: BMS, Novartis, Pfizer. Consultation: BMS, Novartis, Pfizer. All other authors have declared no conflicts of interest.